Pharmacokinetics of lisinopril in hypertensive patients with normal and impaired renal function
- 1 January 1988
- journal article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 34 (1), 61-65
- https://doi.org/10.1007/bf01061419
Abstract
The pharmacokinetics of lisinopril was studied after administration of single and multiple doses of 5 mg to hypertensive patients with normal and impaired renal function. In patients with severe renal failure the peak concentrations were higher, the decline in serum concentration was slower and the time to peak concentration was extended. Accumulation of lisinopril was highly correlated with the creatinine clearance. The effective half-life was doubled and tripled in patients with mild and severe renal impairment, respectively, as compared to patients with a normal renal function. Lisinopril lowered blood pressure in all three groups over 24 h. It is suggested that smaller doses of lisinopril should be administered to patients with severe renal failure.Keywords
This publication has 9 references indexed in Scilit:
- Lisinopril in hypertensive patients with and without renal failureEuropean Journal of Clinical Pharmacology, 1987
- Effect of Food on the Bioavailability of Lisinopril, a Nonsulfhydryl Angiotensin-Converting Enzyme InhibitorJournal of Pharmaceutical Sciences, 1986
- Enalapril (MK421) and its lysine analogue (MK521): a comparison of acute and chronic effects on blood pressure, renin-angiotensin system and sodium excretion in normal man.British Journal of Clinical Pharmacology, 1984
- Antihypertensive efficacy of once daily MK-521, a new nonsulfhydryl angiotensin-converting enzyme inhibitorThe American Journal of Cardiology, 1984
- Enalapril maleate and a lysine analogue (MK‐521) in normal volunteers; relationship between plasma drug levels and the renin angiotensin system.British Journal of Clinical Pharmacology, 1982
- Enalapril maleate and a lysine analogue (MK‐521): disposition in man.British Journal of Clinical Pharmacology, 1982
- Pharmacodynamics of converting enzyme inhibition: the cardiovascular, endocrine and autonomic effects of MK421 (enalapril) and MK521.British Journal of Clinical Pharmacology, 1982
- Effect of a new angiotensin converting enzyme inhibitor MK 421 and its lysine analogue on the components of the renin system in healthy subjects.British Journal of Clinical Pharmacology, 1981
- Drug dosage in patients with renal diseaseClinical Pharmacology & Therapeutics, 1974